Evaxion Partners With Pharmaceutical Company Afrigen Biologics To Develop Novel mRNA Vaccine Against Gonorrhea
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech A/S (NASDAQ:EVAX) has announced a partnership with Afrigen Biologics to develop a novel mRNA vaccine against gonorrhea. The vaccine is based on a candidate identified by Evaxion's EDEN™ platform. The collaboration will also utilize mRNA technology from the WHO and Medicines Patent Pool's mRNA Vaccine Technology Transfer Hub. Afrigen will be responsible for the development and commercialization of the vaccine in LMICs and African territories.
September 20, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evaxion's partnership with Afrigen Biologics to develop a novel mRNA vaccine against gonorrhea could potentially boost the company's profile and market position, especially if the vaccine proves successful.
The partnership with Afrigen Biologics could potentially increase Evaxion's market visibility and credibility, especially if the vaccine proves successful. This could lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100